Elasmogen

Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system.

soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration.

The pipeline targets solid tumour cancers via soloMER-Drug Conjugates and Radioligand Therapies, and systemic inflammatory diseases including inflammatory gut conditions.

The lead oncology programme targets the ROR1 antigen in partnership with Almac Discovery.